Enterprise innovation in action: Validating commercial viability and refining go-to-market strategy for a patient-facing clinical solution

For healthcare enterprises exploring digital opportunities beyond traditional product models, the biggest challenge isn’t generating ideas, it’s deciding which ones are worth pursuing (or not) and how to commercialize them. The Astellas Rx+ Business Accelerator partnered with Rock Health Advisory to evaluate a novel patient-facing digital support concept for post-acute specialty care. The engagement focused on validating demand, pressure-testing assumptions, and designing a viable path forward in a market with few proven analogs.

The challenge: Making high-stakes decisions in an ambiguous market

The Astellas Rx+ Business Accelerator (Rx+ BA) was exploring a patient-facing digital support solution aimed at addressing unmet needs in post-acute specialty care. The concept aligned with Rx+ BA’s ambition to extend innovation beyond pharmaceuticals and explore digitally enabled models that could improve outcomes and patient experience.

From the outset, the Rx+ BA team had a good idea of how the proposed solution would improve health outcomes for patients and wanted to find the most effective way to realize that within the market landscape. The mandate was to combine a clear product vision, strong internal capabilities, and a potential co-development partner with compelling intellectual property to translate into real world patient impact.

Like many enterprises entering novel digital health categories, Rx+ BA faced a familiar set of questions:

• Would health systems and clinicians champion this solution—and under what conditions?
• How would it fit into existing clinical workflows, procurement processes, and reimbursement pathways?
• Was the proposed business model viable at scale, or would it stall after early pilots?
• Were there better partners—or better partnership structures—to support long-term differentiation and favorable deal economics?
• What would success look like financially, and how long would it take to get there?
• And most importantly, how could these components come together to deliver something truly impactful for improved patient health outcomes?

These were not questions that could be answered by market sizing alone. They required an integrated view of clinical reality, commercial dynamics, and partnership strategy before significant resources were committed.

Why Rock Health Advisory: Seeing the opportunity through a different lens

The Astellas Rx+ BA engaged Rock Health Advisory to help bring structure and signal to a highly ambiguous decision.

Rock Health Advisory specializes in evaluating digital health opportunities where traditional benchmarks fall short—categories where solutions are still emerging, buyer behavior is evolving, and success depends on aligning multiple stakeholders. The team brings a rare combination of market intelligence, an ecosystem lens bridging startup and enterprise perspectives, and on-the-ground understanding of how digital health solutions get bought, implemented, and scaled.

For Rx+ BA, partnering with Rock Health offered the ability to see the opportunity through the eyes of health systems, clinicians, and decision-makers while simultaneously modeling what those realities meant for long-term commercial outcomes.

Rock Health Advisory acted as a strategic extension of the Rx+ BA team, working together to challenge assumptions, validate intuition with evidence, and translate complexity into clear decision paths.

The approach: Turning uncertainty into informed choices

The collaboration was structured across five integrated workstreams, each designed to answer a different dimension of “Should we do this—and if so, how?”

• Market Dynamics Assessment
  Rock Health scanned the global landscape to understand how similar problems were being addressed today and where gaps remained. In areas with few direct comparables, the team drew on adjacent digital health models and enterprise trends to contextualize the opportunity and define realistic expectations.
• Business Model Evaluation
  The team pressure-tested monetization pathways, customer segments, and go-to-market assumptions. This analysis surfaced where a default approach might limit adoption or scale and where alternative models could better align with how health systems and patients engage with solutions.
• Clinical Model Assessment
  Rock Health evaluated how the proposed solution would fit into real clinical environments, focusing on workflows, incentives, evidence requirements, and levers for adoption. This helped clarify not just whether the solution was valuable, but whether it would be scalable.
• Commercial Viability Modeling
  The Rock Health team developed scenario-based financial models, translating strategic choices into concrete outcomes—this made explicit the assumptions, dependencies, and levers most likely to influence return on investment and time to profitability.
• Partnership Considerations
  Finally, Rock Health assessed partnership options, comparing the identified co-development partner with alternatives and evaluating different structural pathways (e.g., co-development, licensing, joint venture). This work helped Rx+ BA understand where value would truly be created—and how to structure a partnership to support long-term success.

Impact: Clarity where it matters most

The work delivered:

• A clarified perspective on the opportunities for patient impact
• A clear view of commercial potential under multiple business model scenarios—and what would need to be true for each to succeed
• An evidence-based assessment of partner fit, including differentiation, traction, and long-term viability
• A refined business and go-to-market model aligned with real-world procurement, reimbursement, and clinical realities
• A set of fit-for-purpose value messages and adoption driver recommendations
• A recommendation on partnership structure grounded in data
• A prioritized set of risks and assumptions to test before advancing further

Equally important, the engagement helped the Rx+ BA team align internally—creating a shared understanding of the opportunity, the tradeoffs, and the path forward.

Why this matters for other enterprises

This engagement reflects a challenge many healthcare leaders face today: how to make confident, high-stakes decisions in markets that are still taking shape and impact the lives of patients.

Rock Health Advisory helps enterprises de-risk bets in emerging markets by bringing clarity where comparables are limited. We combine a cross-sector view of digital health with real-world pattern recognition from our network—so leaders can move from intuition to insight to action.

“Thank you so much for the work done on this project. The partnership between our teams, built upon the shared focus on patient impact, was really strong—and we look forward to working with your team again on future consulting needs.”
— Project Lead

At Rock Health Advisory, we use our proprietary datasets, custom frameworks, and deep digital health expertise to help leading enterprises move from intuition to insight, and surface real signals from noise. If you’re looking for help making a high-stakes innovation bet, reach out to us.

And last but not least, stay plugged into the Rock Health community and all things digital health with the Rock Weekly.